The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for vTv Therapeutics Inc is $57.00, about 65.7% above its August 5 closing price of $34.39
VTVT•
